A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease.
10.4166/kjg.2010.56.5.324
- Author:
Yoon Jung JWA
1
;
Nam Hoon KIM
;
Hai Jin PARK
;
Jun Sup PARK
;
Won Ki BAE
;
Kyung Ah KIM
;
June Sung LEE
;
Young Soo MOON
Author Information
1. Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea. n-hkim@paik.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Crohn's disease;
Infliximab;
Psoriasis
- MeSH:
Anti-Inflammatory Agents/*adverse effects/therapeutic use;
Antibodies, Monoclonal/*adverse effects/therapeutic use;
Colonoscopy;
Crohn Disease/diagnosis/*drug therapy;
Female;
Humans;
Psoriasis/*chemically induced/pathology/therapy;
Ultraviolet Rays;
Young Adult
- From:The Korean Journal of Gastroenterology
2010;56(5):324-328
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, opportunistic infections, and the potential for the event such as reactivation of latent tuberculosis. Cutaneous adverse reactions of TNF-alpha agents include skin rash, urticaria, pruritus, lupus-like eruption, and injection site reactions. Most of all, psoriasis or psoriasiform dermatitis induced by infliximab treatment for Crohn's disease is rarely reported in Korea. We report a case of psoriasis induced by infliximab treatment for Crohn's disease with a review of world literature.
